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Abstract: Indiplon is a novel sedative-hypnotic recently approved for the treatment of insom-
nia. Like other non-benzodiazepine hypnotics, its mechanism of action is to modulate subunits, 
especially the alpha-1 subunit, of the GABA receptor complex in order to induce sedation. 
Indiplon was developed in two different formulations to address two different types of insom-
nia complaint: indiplon-IR (immediate release) was designed for sleep onset difﬁ  culties, while 
indiplon-MR (modiﬁ  ed release) was developed for sleep maintenance insomnia. While there 
are currently few peer reviewed articles about indiplon clinical trial results, the early informa-
tion that is available seems to indicate that both formulations have been well tolerated and have 
proven effective at improving both patient reported and objectively measured sleep parameters 
in both adult and elderly insomnia patients. In May 2006, the FDA indicated that indiplon-IR 
was approvable and plans are to resubmit the application in 2007. Indiplon-MR was unapprov-
able and may require further evaluation.
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Introduction
Insomnia is a common sleep disorder with potentially serious economic, health and 
quality of life ramiﬁ  cations if left untreated. It is characterized by symptoms of dif-
ﬁ  culty falling asleep, difﬁ  culty staying asleep, waking too early or poor quality or 
non-restorative sleep (American Psychiatric Association 2000; American Sleep Dis-
orders Association 2001). Epidemiological studies have documented the prevalence 
of chronic insomnia in 10%–15% of the general population (Ford and Kamerow 
1989; Ancoli-Israel and Roth 1999; National Sleep Foundation 2002, 2003, 2004, 
2005; Drake et al 2003). Furthermore, as many as half of all Americans experience 
transient episodes of insomnia symptoms due to acute circumstances (National Sleep 
Foundation 2002, 2003, 2004, 2005).
Chronic insomnia is associated with signiﬁ  cant daytime distress. Consequences 
of the disease can include functional impairment, increased risk of accidents and 
reductions in quality of life (Ford and Kamerow 1989; Balter and Uhlenhuth 1991; 
Rosenthal et al 1993; Zammit 1999). Speciﬁ  c medical conditions associated with 
insomnia include coronary artery disease, hypertension and musculoskeletal problems 
(Gislason et al 1993; Janson et al 2001; Mallon et al 2002). Additionally, numerous 
studies have established a remarkably high association between insomnia and psychi-
atric disorders, especially depression, other affective disorders and anxiety (Ford and 
Kamerow 1989; Benca et al 2004). Evidence of a bidirectional interaction between 
insomnia and other co-morbidities, speciﬁ  cally depression and some pain disorders is 
beginning to emerge (Moldofsky et al 1975; Moldofsky and Scarisbrick 1976). Across 
several studies lasting up to 35 years, insomnia has been shown to increase the risk for 
the development of depression by as much as a factor 5 (Ford 1989; Breslau 1996). 
Meanwhile, pain has been shown to exacerbate sleep difﬁ  culties, while poor sleep 
intensiﬁ  es the perception of pain (Moldofsky et al 1975; Moldofsky and Scarisbrick 
1976; Drewes et al 1997).Neuropsychiatric Disease and Treatment 2007:3(6) 766
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While the underlying causes of insomnia are only 
partially understood, certain risk factors may predispose 
individuals to this disorder. These risk factors include age, 
gender, psychiatric or physical illness, the use of stimulants 
like caffeine and nicotine, some forms of shift work and poor 
sleep hygiene. Other potential contributors, including genetic 
etiology, are the focus of on-going research.
Recently, the serious consequences of insomnia have 
begun to receive more prominent attention. After a hiatus of 
22 years, the National Institutes of Health convened a State 
of the Science conference on chronic insomnia in mid-2005 
(National Institutes of Health 2005). Notably, the conference 
statement recommended that insomnia be considered as either 
a primary disorder or co-morbid with other disorders. Prior 
to this assertion, insomnia was typically considered to be a 
symptom secondary to other medical conditions and, as such, 
was often undertreated. Furthermore in the past few years, 
several new drugs were approved by the FDA for the treat-
ment of insomnia. Greater national attention to the disorder 
and an expanded number of treatment options have resulted 
in marked changes in the pharmaceutical marketplace. Sales 
of prescription sleep aids in the U.S. have markedly increased 
from approximately $900M in 2000 to more than $2.1B in 
2004 (Iskowitz 2005).
Most of the currently available hypnotics are best suited 
to address difﬁ  culties with sleep onset (eg, difﬁ  culty falling 
asleep). Two of the newest treatment options, eszopiclone 
and zolpidem-CR, appear to assist patients with sleep main-
tenance difﬁ  culties (eg, nighttime awakenings). In order to 
minimize the potential for negative events associated with 
residual daytime sedation, all currently approved insomnia 
therapies are recommended to be taken prior to bedtime so 
that a patient can spend a full 8 hours in bed. As information 
about the health impact of insomnia is more widely dissemi-
nated and physicians continue to place more importance on 
its treatment, the number of patients taking prescription sleep 
medicine will continue to grow, as will the need for more 
specialized treatment options.
Current treatment options
Benzodiazepines were among the ﬁ  rst modern drugs devel-
oped to treat the symptoms of insomnia. Benzodiazepines 
speciﬁ  cally approved for this purpose included ﬂ  urazepam 
(Dalmane), temazepam (Restoril), triazolam (Halcion), quaz-
epam (Doral) and estazolam (Prosom) (Eddy and Walbroehl 
1999). This class of drug targets the GABA receptors and 
can produce sedative, hypnotic, anxiolytic, anticonvulsive, 
anesthetic and muscle-relaxant effects (Haefely et al 1992). 
Unfortunately, most benzodiazepines interact with the entire 
GABA receptor complex, creating several of these effects 
simultaneously. Furthermore, short term use of benzodiaz-
epines is recommended because of concerns about tolerance, 
dependence and the potential for signiﬁ  cant adverse events 
(Kales et al 1983; Bixler et al 1987; Adams and Oswald 
1989; Holbrook et al 2000).
More recently, treatment options have grown to include 
non-benzodiazepines and melatonin agonists. The off-label 
usage of other drug classes (eg, antidepressants, antihista-
mines) to treat insomnia complaints is also common, although 
there is limited evidence that these agents are safe and effec-
tive for use in this manner (Hartmann 1995; Nowell et al 
1999; Richardson et al 2002).
In contrast to the benzodiazepines, the non-benzodiazepines 
are more selective for speciﬁ  c GABA receptor subunits asso-
ciated with sedation. These compounds have a rapid onset of 
action and also rapidly eliminated from the body. Thus, they 
are able to quickly induce sedation with fewer of the next-day 
effects associated with some longer acting benzodiazepines 
(Nicholson et al 1983; Walsh et al 1990; Scharf et al 1994; 
Walsh et al 1998; Fry et al 2000). Non-benzodiazepines 
approved for the U.S. market include: zaleplon, zolpidem, 
zolpidem-CR and eszopiclone, the S-isomer of zopiclone. 
Zopiclone is widely used as a sedative outside the U.S.
At present, ramelteon is the only melatonin agonist 
approved for insomnia therapy. It acts on the MT1 and 
MT2 receptors which help maintain the circadian rhythms 
underlying the normal sleep-wake cycle (Brzezinski 1997; 
Hirai et al 2003). An important difference between ramelt-
eon and both the benzodiazepines and non-benzodiazepines 
is that it has not been designated as a scheduled drug by 
the U.S. Drug Enforcement Agency due to its clinically 
established, extremely low potential for abuse (Hirai et al 
2005; Grifﬁ  ths et al 2005; France et al 2006). In addition, 
ramelteon is a completely different way to treat insomnia 
medically, focusing on the melatonin pathway rather than 
the GABA pathway.
Indiplon is one of the newest insomnia treatments in 
the non-benzodiazepine class. In contrast to other members 
of this class, two formulations of indiplon were simultane-
ously developed in order to address two distinct insomnia 
complaints. Indiplon-IR (immediate release) was designed 
to address sleep onset difﬁ  culties, both at the beginning 
of the night and after middle of the night awakenings. 
Indiplon-MR (modiﬁ  ed release) was designed to address 
sleep maintenance difﬁ  culties. The FDA gave Neurocrine 
Biosciences an approvable letter for Indiplon-IR in May 2006 Neuropsychiatric Disease and Treatment 2007:3(6) 767
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and simultaneously stated that the approval of Indiplon-MR 
would require further discussions and potentially additional 
development efforts.
Pharmacology of indiplon
Indiplon is a novel pyrazolopyrimidine with the empiric 
formula C20H16N4O2S. It is chemically described as 
N-Methyl-N-[3-[3-(thien-2-ylcarbonyl)pyrazolo[1,5α]
pyrimidin-7-yl]phenyl]acetamide.
Indiplon pharmacokinetics (PK) have been investi-
gated in both animal and human studies. Healthy young 
male and female humans have demonstrated a maximal 
concentration (Cmax) of indiplon at 0.73 and 0.82 hours 
after dosing and exhibited an elimination half life (t1/2) of 
1.97 and 1.71 hours, respectively (Rogowski et al 2002). 
Even though slight gender differences were observed, 
they were not statistically significant. Another study 
comparing indiplon PK in healthy adult and elderly sub-
jects found that indiplon’s peak plasma concentration 
was reached in 2.3 hours and the elimination half life was 
1.5 hours in the younger group, as compared to 2.7 hours 
and 1.8 hours in the older group (Jochelson et al 2002). 
Again, these differences did not prove to be statistically 
significant.
Differences in PK values due to gender and age are 
frequently observed with both other hypnotics. Maximum 
concentration, total exposure and half life can be up to 
50% greater in women (Rosen et al 1999; Greenblatt et al 
2000). In the elderly, impaired renal and hepatic function 
can lead to a 3-fold increase in plasma concentrations and 
a doubling of half-life relative to the values seen younger 
adults. PK differences due to gender have been associated 
with metabolization via the hepatic isoform CYP 3A4, while 
age differences have been linked to the cytochrome P450 
metabolic pathway (Greenblatt et al 1991, 2000). Indiplon 
is metabolized equally by CYP 3A4 and non-microsomal 
esterases, potentially explaining its relative lack of gender 
and age effects as compared to other hypnotics.
Of the currently available treatments, zaleplon is the 
only non-benzodiazepine hypnotic of the pyrazolopyrimi-
dine class, the same chemical class as indiplon. Compared 
to indiplon, zaleplon has a somewhat shorter time to peak 
plasma concentration at approximately one hour as well as 
a shorter elimination half life of approximately one hour. 
The pharmacokinetics of zaleplon do not vary signiﬁ  cantly 
with age or gender, however hepatic impairment can lead 
to a 4–7-fold increase in plasma concentration, a ﬁ  nding 
similar to indiplon.
While indiplon has not been shown to interact with 
alcohol, zaleplon potentiates the CNS-impairing effects for 
1–2.5 hours after co-administration. Finally, zaleplon, like 
indiplon, shows no development of tolerance during short 
term nightly administration.
A signiﬁ  cant difference between these two compounds 
is that indiplon is 10 times more selective for the GABA-A 
alpha 1 subunit, which is associated with sedation, compared 
to the alpha 2, 3 or 5 subunits. Zaleplon is only twice as 
selective for the alpha 1 subunit.
Co-administration of indiplon and alcohol does has not 
been shown to produce any pharmacokinetic or phar-
macodynamic (PD) interactions (Berkowitz et al 2003). 
The absence of effect on PK values is expected since 
alcohol and indiplon are eliminated via different meta-
bolic pathways. However, the absence of impact on PD 
parameters is noteworthy and unique relative to many 
other hypnotics.
Finally, the potential for indiplon to produce tolerance 
was evaluated in healthy volunteers (Jochelson, Chen 
et al 2003). Both PK and PD parameters were essentially 
unchanged between the first and last day of the two week 
study at all dose levels (10–40 mg), indicating no devel-
opment of tolerance following repeat administration of 
indiplon.
Indiplon in clinical trials
Indiplon was developed by Neurocrine Biosciences in two 
distinct formulations. The immediate release form (-IR) 
was designed to address sleep onset difﬁ  culties, while 
the modiﬁ  ed release form (-MR) was developed to help 
patients stay asleep throughout the entire night. The FDA 
gave Neurocrine an approvable letter for indiplon-IR 5 and 
10 mg in May 2006. Neurocrine plans to resubmit the appli-
cation in mid-year 2007 after conducting further analyses 
and modiﬁ  cations to previous analyses. A supplemental 
pharmacokinetic/food effect proﬁ  le was also requested by 
the FDA and has been completed. Indiplon-MR 15 mg was 
found unapprovable. At the time of this review, Neurocrine 
may continue to evaluate the MR formulation for sleep 
maintenance insomnia.
Most of the currently available data on indiplon comes 
from either abstracts written by researchers involved in 
studies sponsored by Neurocrine or from corporate press 
releases. These studies are summarized in Table 1. Additional 
information from these trials will likely become available 
as the company begins the market launch of one or both 
formulations of the drug.Neuropsychiatric Disease and Treatment 2007:3(6) 768
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Indiplon-IR
Indiplon-IR has been studied in both healthy volunteers and 
in patients meeting the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV®) criteria for primary insomnia 
for at least three months (American Psychiatric Association 
2000). Two studies induced transient insomnia in healthy 
adults via a 2-hour phase advance and the sleep laboratory 
“ﬁ  rst night effect.” The impact of indiplon-IR relative to 
placebo was objectively measures using polysomnography 
(PSG) in both of these trials (Roth et al 2003; Scharf et al 
2004). Objective Latency to Persistent Sleep (LPS) and patient 
reported Latency to Sleep Onset (LSO) were both signiﬁ  cantly 
improved with all four doses evaluated (10 and 20 mg in 
the 1st study, 15 and 30 mg in the 2nd). The ﬁ  rst study also 
found that indiplon-IR produced signiﬁ  cant improvements in 
objective and subjective Total Sleep Time (TST, sTST), sleep 
efﬁ  ciency and several measures of sleep quality.
Two placebo-controlled trials studied the effects of 
indiplon-IR (10 and 20 mg) in adults with primary insomnia. 
The ﬁ  rst trial used PSG to measure patient sleep parameters 
at the beginning of the ﬁ  rst, third and ﬁ  fth weeks of treat-
ment (Walsh et al 2004). Relative to placebo, both doses 
of indiplon signiﬁ  cantly reduced LPS and patient reports 
of LSO were also signiﬁ  cantly improved at weeks 1 and 5. 
Signiﬁ  cant improvements were also seen in TST (10 mg 
only) and sleep quality (both doses) at week 1. The second 
study evaluated subjective sleep parameters over the course 
of three months (Scharf et al 2005). Patients in this trial 
reported that indiplon-IR signiﬁ  cantly improved the time to 
sleep onset, sTST, subjective Wake time After Sleep Onset 
(sWASO) and sleep quality at all time points. A subset of 
the study population continued treatment for up to 6 months. 
Improvements in sleep onset were maintained throughout 
this period of time.
Indiplon-IR was evaluated in two trials with elderly 
insomnia patients. The ﬁ  rst was a dose response study com-
paring the effects of 5, 10 and 20 mg of indiplon-IR with 
placebo (Scharf et al 2003). All doses were shown to produce 
signiﬁ  cant improvements in LPS, LSO, sTST and sleep 
quality. The second study used patient reports to evaluate 
Table 1 Indiplon (-IR and -MR) studies
Authors  Patients (N)  Indiplon dosage  Duration
Rogowski et al 2002   Healthy adults (24)  IR: 15 mg  1 day
Berkowitz et al 2003  Healthy adults (10)  IR: 10 mg  1 day
Roth et al 2003  Healthy adults (228)  IR: 15, 30 mg  1 day
Scharf et al 2004   Healthy adults (593)  IR: 10, 20 mg  1 day
Garber et al 2004  Healthy adults (35)  IR: 10, 20 mg  1 day
Jochelson, Chen et al 2003  Healthy adults (30)  IR: 10, 30, 45 mg  2 weeks
Jochelson et al 2002  Healthy adults  and elderly (25)  IR: 15 mg  4 days
Neurocrine Biosciences 2003  Healthy elderly (36)  IR: 5, 10 mg  1 day
Roth et al 2005  Chronic insomniacs (260)  IR: 10, 20 mg  4 weeks
Walsh et al 2004  Chronic insomniacs (194)  IR: 10, 20 mg  5 weeks
Scharf et al 2005  Chronic insomniacs (702)  IR: 10, 20 mg  3 months
Black et al 2006  Chronic insomniacs (536)  IR: 10, 20 mg  12 months
Scharf et al 2003  Elderly chronic insomniacs (42)  IR: 5, 10, 20 mg  1 day
Walsh et al 2005  Elderly chronic insomniacs (358)  IR: 5, 10 mg  2 weeks
Moscovitch et al 2006  Elderly chronic insomniacs (121)  IR: 5, 10 mg  6 months
Corrigan et al 2006  Healthy adults  IR: up to 30 mg  various
Cohn et al 2004  Healthy adults (12)  MR: 30 mg  1 day
Jochelson, Bozigian et al 2003  Healthy adults (36)  MR: 40 mg  1 day
Neurocrine Biosciences 2004d  Healthy adults (325)  MR: 20, 30 mg  1 day
Hull et al 2004  Adults with mild to moderate   MR: 20 mg  1 day
 chronic  obstructive
  pulmonary disease (18)   
Jochelson et al 2004  Chronic insomniacs (211)  MR: 30 mg  2 weeks
Klee et al 2006  Chronic insomniacs (248)  MR: 15 mg  4 weeks
Neurocrine Biosciences 2004b  Chronic insomniacs (740)  MR: 20, 30 mg  3 months
Rosenberg et al 2006  Adult and elderly chronic  MR: 15 mg  2 days
 insomniacs  (100)   
Walsh et al 2003  Elderly chronic insomniacs (60)  MR: 10, 20, 30, 35 mg  2 days
Lankford et al 2005  Elderly chronic insomniacs (229)  MR: 15 mg  2 weeks
Neurocrine Biosciences 2004c  Elderly chronic insomniacs (220)  MR: 20 mg  2 weeks
Neurocrine Biosciences 2004a  Elderly chronic insomniacs (340)  MR: 20, 30 mg  5 weeksNeuropsychiatric Disease and Treatment 2007:3(6) 769
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the effects of 5 and 10 mg of indiplon relative to placebo 
(Walsh et al 2005). Both dose levels produced signiﬁ  cant 
improvements in LSO, sTST, the subjective Number of 
Awakenings (sNAW) and sleep quality during throughout the 
2 week treatment period. Additionally, the 10 mg dose group 
showed signiﬁ  cantly improvement in sWASO at both time 
points. Again, treatment was continued for up to 6 months for 
a subset of the patients in this trial (Moscovitch et al 2006). 
Over this extended timeframe, 81% of the study participants 
randomized to indiplon-IR reported that it improved their 
sleep (72% on 5 mg, 92% on 10 mg).
Indiplon-MR
Indiplon-MR is an extended release formulation that deliv-
ers part of its dose initially and then provides a controlled 
release of the remainder over the course of the night. It 
has been tested in studies involving healthy volunteers and 
in insomnia patients. Transient insomnia was induced in 
healthy adults via the sleep laboratory model of the “ﬁ  rst 
night effect” and a 2-hour phase advance (Neurocrine Bio-
sciences 2004d). As compared to placebo, PSG measured 
LPS and subjective LSO were signiﬁ  cantly reduced for both 
doses studied (20 and 30 mg). A second study in healthy 
adults used repeated venipunctures to simulate sleep main-
tenance difﬁ  culties (Jochelson, Bozigian et al 2003). In this 
evaluation, indiplon-MR 40 mg signiﬁ  cantly improved LSO, 
sTST and sleep quality relative to placebo. The subjective 
number of awakenings declined non-signiﬁ  cantly, likely 
due to the stimulus created by multiple instances of blood 
sampling.
All other indiplon-MR studies were performed with 
insomnia sufferers, including three trials using adult patients. 
The ﬁ  rst of these three studies randomized patients to either 
30 mg of indiplon-MR or placebo (Jochelson et al 2004). 
Sleep continuity, as measured by sTST, sWASO and sNAW, 
was signiﬁ  cantly improved during the two weeks of treat-
ment with indiplon. Sleep onset and quality also showed 
signiﬁ  cantly improvements at all time points.
The second study lasted for three months and treated 
the adult patients with either indiplon-MR (20 or 30 mg) or 
placebo (Neurocrine Biosciences 2004b). Again, measures 
of sleep maintenance (sTST, subjective Total Wake Time 
(sTWT), sWASO and sNAW) were signiﬁ  cantly improved 
for both doses over the length of the trial. Participants also 
reported signiﬁ  cant improvements in sleep quality and LSO. 
The third and ﬁ  nal trial in adults compared the indiplon-MR 
dose submitted for FDA approval (15 mg) with placebo 
(Klee et al 2006). Patient reports demonstrated signiﬁ  cant 
improvements in sTST, sWASO, sNAW, sTWT, LSO and 
sleep quality over the course of the 4 week long study.
Both adult and elderly insomnia patients participated in 
a placebo-controlled, cross-over PSG study of indiplon-MR 
15 mg (Rosenberg et al 2006). Active treatment produced 
signiﬁ  cant improvements in all objective measures of sleep 
maintenance (WTDS, WASO and TST) and sleep onset. 
LSO and sleep quality were also signiﬁ  cantly improved. 
Notably, at present this is the only study in the public 
domain that uses PSG to objectively evaluate indiplon-MR 
15 mg in adult patients – the dose submitted to the FDA 
for approval.
Indiplon-MR has been tested in four trials with elderly 
insomnia patients. The ﬁ  rst of these was a PSG dose-response 
study comparing indiplon-MR 10, 20, 30 and 35 mg with 
placebo (Walsh et al 2003). In this trial, signiﬁ  cant improve-
ments in WASO and mean sleep efﬁ  ciency were seen for 
indiplon-MR doses of 20 mg and above. Relative to placebo, 
signiﬁ  cant improvements in LPS and NAW were demon-
strated by all dose levels of active treatment.
Elderly chronic insomnia patients with sleep maintenance 
difﬁ  culties participated in a two week trial of indiplon-MR 
20 mg (Neurocrine Biosciences 2004c). At all time points, 
both sTST and sWASO were signiﬁ  cantly improved with 
treatment. Two investigator global rating scales, subjective 
sleep maintenance endpoints (sTWT, sNAW), sleep onset 
and quality were also signiﬁ  cantly improved relative to 
placebo. In another study with elderly patients, indiplon-MR 
20 and 30 mg were compared with placebo over a period 
of 5 weeks (Neurocrine Biosciences 2004a). PSG mea-
sured sleep maintenance (WASO, TST, WTDS, and sleep 
efﬁ  ciency) and onset (LPS) were signiﬁ  cantly improved at 
all time points. Furthermore, relative to those on placebo, 
indiplon-MR patients also reported that their sleep quality 
improved signiﬁ  cantly.
Finally, the indiplon-MR dose submitted to the FDA 
for approval (15 mg) was evaluated in 229 elderly insom-
nia patients (Lankford et al 2005; Lydiard et al 2006) in a 
manner similar to that of the adult insomnia patient trial of 
indiplon-MR 15 mg previously mentioned (Klee et al 2006). 
As in the adult patient study, the participants in this evalua-
tion reported signiﬁ  cant improvement in all sleep measures 
at all time points. Measures evaluated included sTST, LSO, 
sWASO, sNAW, sTWT and sleep quality.
Safety and tolerability of indiplon
Indiplon’s safety and tolerability has been assessed in all 
of the studies reviewed. Overall, few adverse events were Neuropsychiatric Disease and Treatment 2007:3(6) 770
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produced by either formulation, and those that did occur were 
principally consistent with the known effects of hypnotics.
Adverse events were evaluated over the course of a 
12 month trial in adult insomnia patients randomized to 
placebo or indiplon-IR 10 or 20 mg (Black et al 2006). The 
most frequent adverse events seen at the 20 mg dose level 
were headaches (8.7%), URI (6.5% and nasopharyngitis 
(5.9%). The 10 mg group reported headaches (11.8%), back 
pain and somnolence (both 7.9%). Over the course of the 
study no clinically relevant changes in vital signs or ECG 
parameters occurred.
Several pharmacodynamic tests were used across 
multiple trials to measure the next-day effects of indiplon. 
The Visual Analog Scales of sleepiness (VAS) was used 
to measure next day sedation, while the Digit Symbol 
Substitution Test (DSST) and Symbol Copying Test (SCT) 
were both used to evaluate residual functional impairment. 
Across four trials (Roth et al 2003; Scharf et al 2003, 2004; 
Walsh et al 2004) no changes in any of these next-day 
measures was observed at any dose level of indiplon-
IR studied (5 to 30 mg). Evaluations of indiplon-MR’s 
residual effects have been reported for two trials. Only the 
highest dose evaluated (35 mg) was shown to produce a 
modest effect on DSST scores (Walsh et al 2003; Lydiard 
et al 2006). No other impairment or evidence of residual 
sedation was found.
The potential for the development of tolerance and with-
drawal symptoms resulting from indiplon was examined 
across several studies. A 2-week repeat dosing study in 
healthy volunteers found no evidence of PK or PD toler-
ance with indiplon-IR (Jochelson, Chen et al 2003). Three 
additional trials in insomnia sufferers incorporated the 
Benzodiazepine Withdrawal Symptom Questionnaire (Walsh 
et al 2004, 2005; Scharf et al 2005). Using this scale, no signs 
of withdrawal were found during treatment that lasted up to 
3 months with indiplon-IR 5 to 20 mg.
In spite of warnings against doing so, insomnia patients 
often consume hypnotics and alcohol together. Co-
administration of these compounds often leads to changes in 
drug PK which may, in turn, result in additive impairment. 
The interaction of indiplon-IR and alcohol was evaluated 
to assess the likelihood of these effects (Berkowitz et al 
2003). This study found a small, non-additive reduction in 
performance on pharmacodynamic tests (DSST and SCT). 
Reaction time and sedation (VAS) were unaffected.
Studies of healthy volunteers have assessed the potential 
for drug-drug interactions between indiplon and several other 
compounds (Corrigan et al 2006). These evaluations have 
found that indiplon does not impact the PK of either digoxin 
or theophylline. The PK and PD of warfarin also remained 
unaffected. Co-administration of indiplon with antidepres-
sants (sertraline, paroxetine, venlafaxine, amitriptyline) does 
not result in additive effects on PD assessments and appears 
to have no effect on indiplon’s PK values.
Respiratory depression in individuals with chronic 
obstructive pulmonary disease (COPD) and sleep apnea has 
been observed when individuals from these at-risk group use 
benzodiazepine hypnotics. Unfortunately, sleep apnea and 
COPD are strongly linked with co-morbid insomnia, creating 
complex treatment trade-offs (Fleetham et al 1982; Weiss 
et al 2000). Indiplon-MR’s respiratory depressant effects 
were assessed in COPD patients to evaluate the risk indiplon 
presents for this patient subset (Hull et al 2004). Relative to 
placebo, no changes in either the arterial oxygen saturation 
level or the respiratory disturbance index were produced by 
single night of indiplon-MR 20 mg. Additionally, half of 
the individuals receiving indiplon reported “very good” or 
“excellent” sleep quality vs only 17% of those randomized 
to placebo. Indiplon-MR 30 mg was compared to codeine 
sulfate 60 mg (active control) and placebo in a daytime 
CO2 challenge model (Cohn et al 2004). After dosing with 
codeine, healthy volunteers experienced respiratory sup-
pression for 8 hours. In contrast, no respiratory effects were 
demonstrated at any time point following administration of 
indiplon.
Finally, middle of the night dosing with indiplon-IR 
was evaluated. Existing therapeutics are not appropriate for 
insomniacs who awaken in the middle of the night and have 
difﬁ  culties returning to sleep because these medications’ 
relatively long duration of action can produce signiﬁ  cant next 
day impairments when taken with less than 8 hours available 
time in bed. The next-day effects of taking indiplon-IR with 
only 4 hours remaining time in bed were studied in three 
separate trials. Two of these trials also incorporated other 
hypnotics as comparators.
A single-night, cross-over study in healthy adults woke 
participants after they had spent only 4 hours in bed (Garber 
et al 2004). Volunteers were dosed with either indiplon-IR 
(10 or 20 mg), zolpidem 10 mg, zopiclone 7.5 mg or placebo 
and were then permitted to remain in bed for another 
4 hours before being awakened a second time. Participants 
performed the DSST, SCT and VAS at 4 and 6 hours post-
dose to assess the relative next-day residual effects of study 
treatment. Relative to placebo, indiplon-IR was the only 
drug that did not produce any signiﬁ  cant changes on any 
of these tests. Zolpidem produced a signiﬁ  cant increase in Neuropsychiatric Disease and Treatment 2007:3(6) 771
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sleepiness at 4 hours post-dose and signiﬁ  cantly increased 
sedation was seen at both 4 and 6 hours post-dose with 
zopiclone.
Healthy elderly volunteers participated in a similar 
trial comparing the effects of 5 and 10 mg of indiplon-IR, 
following middle of the night dosing, with those resulting 
from 3.75 mg of zopiclone and placebo (Neurocrine Bio-
sciences 2003). As in the study with young adults, neither 
dose of indiplon-IR produced any signiﬁ  cant changes on 
the DSST, SCT or VAS at any time point. Participants 
randomized to zopiclone, however, demonstrated signiﬁ  -
cant changes on the DSST at 4 and 8 hours post-dose and 
showed a trend toward impairment on the SCT at both 4 
and 6 hours post-dose.
The third study of middle of the night dosing was con-
ducted in adult insomnia patients on an outpatient basis 
(Roth et al 2005). Over the course of 4 weeks, double-blind 
therapy (indiplon-IR 10 or 20 mg, placebo) was self admin-
istered on a prn basis as long as at least 4 hours sleep time 
was available to the patient. Participants reported that LSO 
post-dose was signiﬁ  cantly shortened at all time points. 
Furthermore, over the course of the study, the average sTST 
was signiﬁ  cantly extended for patients randomized to both 
doses of indiplon-IR relative to those treated with placebo. 
VAS ratings showed no increase in next day sleepiness at 
either dose of active treatment.
Summary
Indiplon is a novel sedative-hypnotic that modulates subunits 
of the GABA receptor complex in order to induce seda-
tion. It has been shown to be well tolerated and effective 
as an insomnia therapy in randomized, placebo-controlled 
trials involving more than 7,500 participants. Both patient 
reported and objectively measured sleep parameters have 
shown consistent improvements without next-day residual 
sedation or impairment. Indiplon was developed in two dif-
ferent formulations to address two different types of insomnia 
complaint: indiplon-IR (immediate release) was designed for 
sleep onset difﬁ  culties, while indiplon-MR (modiﬁ  ed release) 
was developed for sleep maintenance insomnia. Indiplon-
IR shows potential for use on a prn basis, for example, by 
patients who wake in the middle of the night and are unable 
to return to sleep without assistance.
Disclosures
Dr Lankford has been an investigator in clinical trials covered 
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